دورية أكاديمية
أعرض في EDS

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.

التفاصيل البيبلوغرافية
العنوان: Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.
المؤلفون: Stokes ME; Informatics and Predictive Sciences, Bristol Myers Squibb, Summit, NJ, USA., Wenzl K; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Huang CC; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Ortiz M; Informatics and Predictive Sciences, Bristol Myers Squibb, Seville, Spain., Hsu CC; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Maurer MJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Stong N; Informatics and Predictive Sciences, Bristol Myers Squibb, Summit, NJ, USA., Nakayama Y; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Wu L; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Chiu H; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Polonskaia A; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Danziger SA; BMS at the time the study was conducted, Amazon, Seattle, WA, USA., Towfic F; BMS at the time the study was conducted, Prometheus Biosciences, San Diego, CA, USA., Parker J; LifeEDIT Therapeutics, Research Triangle Park, Durham, NC, USA., King RL; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Link BK; Division of Hematology, Oncology, Blood and Marrow Transplant, University of Iowa, Iowa City, IA, USA., Slager SL; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Sarangi V; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Asmann YW; Department of Health Science Research, Mayo Clinic, Jacksonville, FL, USA., Novak JP; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Sudhindra A; Clinical Research and Development, Bristol Myers Squibb, Summit, NJ, USA., Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hagner PR; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Cerhan JR; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Novak AJ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gandhi AK; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA. anita.gandhi@bms.com.
المصدر: Nature communications [Nat Commun] 2024 Aug 08; Vol. 15 (1), pp. 6790. Date of Electronic Publication: 2024 Aug 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Lymphoma, Large B-Cell, Diffuse*/genetics , Lymphoma, Large B-Cell, Diffuse*/immunology , Lymphoma, Large B-Cell, Diffuse*/pathology , Proto-Oncogene Proteins c-myc*/genetics , Proto-Oncogene Proteins c-myc*/metabolism , Transcriptome* , Lenalidomide*/therapeutic use , Lenalidomide*/pharmacology , Gene Expression Regulation, Neoplastic* , Ikaros Transcription Factor*/genetics , Ikaros Transcription Factor*/metabolism , Transcription Factor 4*/genetics , Transcription Factor 4*/metabolism, Humans ; B-Lymphocytes/metabolism ; B-Lymphocytes/immunology ; Prognosis ; Animals ; Cell Line, Tumor ; Gene Expression Profiling/methods ; Mice ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; DNA Copy Number Variations
مستخلص: Immunochemotherapy has been the mainstay of treatment for newly diagnosed diffuse large B-cell lymphoma (ndDLBCL) yet is inadequate for many patients. In this work, we perform unsupervised clustering on transcriptomic features from a large cohort of ndDLBCL patients and identify seven clusters, one called A7 with poor prognosis, and develop a classifier to identify these clusters in independent ndDLBCL cohorts. This high-risk cluster is enriched for activated B-cell cell-of-origin, low immune infiltration, high MYC expression, and copy number aberrations. We compare and contrast our methodology with recent DLBCL classifiers to contextualize our clusters and show improved prognostic utility. Finally, using pre-clinical models, we demonstrate a mechanistic rationale for IKZF1/3 degraders such as lenalidomide to overcome the low immune infiltration phenotype of A7 by inducing T-cell trafficking into tumors and upregulating MHC I and II on tumor cells, and demonstrate that TCF4 is an important regulator of MYC-related biology in A7.
(© 2024. The Author(s).)
References: Cancers (Basel). 2021 Dec 07;13(24):. (PMID: 34944787)
PLoS One. 2019 Nov 19;14(11):e0224693. (PMID: 31743345)
Nature. 2000 Feb 3;403(6769):503-11. (PMID: 10676951)
Sci Transl Med. 2019 Jun 19;11(497):. (PMID: 31217338)
Blood. 2020 Mar 26;135(13):996-1007. (PMID: 31977002)
Cancer Cell. 2012 Sep 11;22(3):359-72. (PMID: 22975378)
CA Cancer J Clin. 2016 Nov 12;66(6):443-459. (PMID: 27618563)
Blood. 2018 May 3;131(18):2060-2064. (PMID: 29475959)
Methods Mol Biol. 2018;1711:243-259. (PMID: 29344893)
Int J Epidemiol. 2017 Dec 1;46(6):1753-1754i. (PMID: 29025017)
N Engl J Med. 2021 Mar 4;384(9):842-858. (PMID: 33657296)
Clin Cancer Res. 2022 Aug 2;28(15):3367-3377. (PMID: 35583604)
Nat Med. 2018 May;24(5):679-690. (PMID: 29713087)
Blood Cancer J. 2020 Nov 9;10(11):117. (PMID: 33168821)
J Clin Oncol. 2019 Jan 20;37(3):202-212. (PMID: 30523719)
Cancer Cell. 2012 Jun 12;21(6):723-37. (PMID: 22698399)
N Engl J Med. 2018 Apr 12;378(15):1396-1407. (PMID: 29641966)
Blood. 2023 May 18;141(20):2493-2507. (PMID: 36302166)
Blood. 2015 Aug 6;126(6):779-89. (PMID: 26002965)
Br J Haematol. 2013 Feb;160(4):487-502. (PMID: 23252516)
Leukemia. 2024 Mar;38(3):610-620. (PMID: 38158444)
Blood. 2020 Mar 26;135(13):1008-1018. (PMID: 31977005)
Cancer Cell. 2020 Apr 13;37(4):551-568.e14. (PMID: 32289277)
Cell Death Discov. 2022 Mar 15;8(1):117. (PMID: 35292660)
Blood. 2020 May 14;135(20):1759-1771. (PMID: 32187361)
Cancer Cell. 2023 Oct 9;41(10):1705-1716.e5. (PMID: 37774697)
Blood. 2021 Apr 22;137(16):2196-2208. (PMID: 33120427)
Science. 2014 Jan 17;343(6168):301-5. (PMID: 24292625)
Nat Protoc. 2018 Jun;13(6):1488-1501. (PMID: 29844525)
Science. 2022 Nov 4;378(6619):549-553. (PMID: 36378961)
Curr Cancer Drug Targets. 2010 Mar;10(2):155-67. (PMID: 20088798)
Leukemia. 2021 Feb;35(2):522-533. (PMID: 32139889)
Nat Commun. 2021 Sep 23;12(1):5606. (PMID: 34556668)
Br J Haematol. 2014 Mar;164(6):811-21. (PMID: 24328678)
Blood Cancer J. 2024 Jun 20;14(1):100. (PMID: 38902256)
N Engl J Med. 2022 Jan 27;386(4):351-363. (PMID: 34904799)
Br J Haematol. 2017 Nov;179(3):399-409. (PMID: 28771673)
J Clin Oncol. 2021 Apr 20;39(12):1317-1328. (PMID: 33621109)
J Immunol. 2015 Feb 15;194(4):1434-45. (PMID: 25595783)
J Immunol. 2007 Jun 1;178(11):6840-8. (PMID: 17513732)
Lancet Oncol. 2019 May;20(5):649-662. (PMID: 30948276)
Cell. 2017 Oct 5;171(2):481-494.e15. (PMID: 28985567)
Blood Adv. 2022 Feb 8;6(3):1025-1037. (PMID: 34941996)
Cancer Discov. 2021 Jun;11(6):1468-1489. (PMID: 33541860)
BMC Bioinformatics. 2013 Jan 16;14:7. (PMID: 23323831)
Front Oncol. 2020 Dec 02;10:584095. (PMID: 33344238)
Mod Pathol. 2015 Dec;28(12):1555-73. (PMID: 26541272)
Cancer Cell. 2012 Oct 16;22(4):547-60. (PMID: 23079663)
Cancer Cell. 2021 Oct 11;39(10):1422-1437.e10. (PMID: 34597589)
J Clin Oncol. 2019 Jan 20;37(3):190-201. (PMID: 30523716)
Science. 2014 Jan 17;343(6168):305-9. (PMID: 24292623)
Cell. 2012 May 25;149(5):994-1007. (PMID: 22608083)
J Clin Oncol. 2017 Nov 1;35(31):3529-3537. (PMID: 28796588)
J Clin Oncol. 2014 Apr 1;32(10):1066-73. (PMID: 24550425)
J Clin Oncol. 2019 May 20;37(15):1285-1295. (PMID: 30901302)
معلومات مُعتمدة: U01 CA195568 United States CA NCI NIH HHS; CA195568 U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI); CA97274 U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI); R01 CA212162 United States CA NCI NIH HHS; P50 CA097274 United States CA NCI NIH HHS; CA212162-01A1 U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
المشرفين على المادة: 0 (Proto-Oncogene Proteins c-myc)
F0P408N6V4 (Lenalidomide)
0 (MYC protein, human)
148971-36-2 (Ikaros Transcription Factor)
0 (Transcription Factor 4)
0 (TCF4 protein, human)
0 (IKZF1 protein, human)
0 (IKZF3 protein, human)
تواريخ الأحداث: Date Created: 20240808 Date Completed: 20240808 Latest Revision: 20240811
رمز التحديث: 20240812
مُعرف محوري في PubMed: PMC11310352
DOI: 10.1038/s41467-024-50830-y
PMID: 39117654
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-024-50830-y